



February 2011

**Re: Discontinuation
7.5 mg and 15 mg OPANA[®] ER (oxymorphone HCl) Extended-Release Tablets CII**

Dear Valued Customer:

Please be advised that Endo Pharmaceuticals will discontinue the sale and distribution of two strengths of Opana[®] ER (oxymorphone HCl) Extended-Release Tablets CII. Endo estimates these two strengths will no longer be on retail shelves on or about **May 01, 2011**.

NDC	Product	Description	Packaging
63481-0522-70	Opana [®] ER (oxymorphone HCl) Extend-Release Tablets CII	7.5 mg	100 ct. Bottles
63481-0553-70	Opana [®] ER (oxymorphone HCl) Extend-Release Tablets CII	15 mg	100 ct. Bottles

Due to increased demand for Opana ER, Endo is streamlining operations to focus on the most commonly prescribed dosages, enabling us to serve the needs of our customers while continuing to supply a wide range of dose strengths. **Opana[®] ER dose strengths of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg will continue to be available at your local pharmacy.** Your patients can call 1-888-222-9845 to locate the nearest pharmacy stocking their prescribed strength of Opana ER.

Please see the enclosed full Prescribing Information including boxed warning for Opana[®] ER.

We thank you for your continued support of Endo Pharmaceuticals Inc. If you have any questions please consult with your local Endo Pharmaceuticals Sales Representative or contact the Endo Pharmaceuticals Customer Service at 1-800-462-ENDO (3636).

Sincerely,

A. Demir Bingol
Senior Director, Oral Pain Solutions